Skip to content
2000
Volume 11, Issue 7
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

At present cancer treatment is still a confusing problem. Great progress has been made in anti-tumor agents since a series of small molecules are approved by FDA as anti-tumor drugs. Nitroimidazoles is a kind of radiosensitizer with multiple bioactivities used in cancer treatment since 1950s. In this review, we focus on the development of nitroimidazoles as radiosensitizer, bio-reductive prodrug and other types of anti-tumor agents for cancer therapy, and the mechanism of acting as anti-tumor agents. Finally, we also discuss the prospect and developmental trend of nitroimidazoles as anti-tumor agents.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/187152011796817664
2011-09-01
2025-04-02
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/187152011796817664
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test